Safety Remains Front-Line Concern For Oral MS Drugs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Two drugs in a race to become the first oral treatment for relapsing forms of multiple sclerosis have high safety hurdles to overcome, obstacles that may knock them both out of the running as first-line treatments.